Diagnostic value of urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 for acute kidney injury: a meta-analysis

Table 1 Characteristics of the included studies

First author, year [reference]	Location	Design	Setting	AKI threshold	Sample size (n)	AKI (n)	Non-AKI (n)	Sampling time	Assay
Kashani, 2013 [8]	North America and Europe	PC	ICU	KDIGO stage 2 or 3 within 12 h	728	101	617	At enrollment	NephroCheck test (Astute Medical, San Diego, CA, USA)
Bihorac, 2014 [21]	USA	PC	ICU	KDIGO stage 2 or 3 within 12 h	408	71	337	At enrollment	NephroCheck test
Hoste, 2014 [22]	USA	PC	ICU	KDIGO stage 2 or 3 within 12 h	153	27	126	At enrollment	NephroCheck test
Meersch, 2014 [23]	Germany	PC	CS with CPB	KDIGO stage 1 within 72 h	50	26	24	4 h after coming off CPB	NephroCheck test
Wetz, 2015 [24]	Germany	PC	CS with CPB	KDIGO stage 1 within 2 postoperative days	42	16	26	Day 1 after surgery	NephroCheck test
Pilarczyk, 2015 [25]	USA	PC	CABG	KDIGO stage 2 or 3 within 48 h	60	6	54	Day 1 after surgery	NephroCheck test
Gocze, 2015 [26]	Germany	PC	Surgery in ICU	KDIGO stage 1 within 48 h	107	45	62	At enrollment	NephroCheck test
Kimmel, 2016 [27]	Germany	PC	ED	KDIGO stage 2 or 3 within 12 h	298	46	252	Within 24 h	NephroCheck test
Dusse, 2016 [28]	Germany	PC	TAVI	KDIGO stage 2 or 3 within 48 h	40	8	32	Day 1 after surgery	NephroCheck test

Abbreviations: AKI Acute kidney injury, ICU Intensive care unit, ED Emergency department, KDIGO Kidney Disease: Improving Global Outcomes, PC Prospective cohort, CS Cardiac surgery, CPB Cardiopulmonary bypass, CABG Coronary artery bypass surgery, TAVI Transcatheter aortic valve implantation

ISSN: 1364-8535